A CEO Sold Stock Right Before His Company Announced Record Profits. Here Is What It Means.
By Rachel Whitman, Civic Pulse
August 6, 2026 – When the president and CEO of a major biotech firm sells shares, it usually raises eyebrows. But a closer look at the recent transaction by Arcutis Biotherapeutics CEO Todd Watanabe reveals a story less about cashing out and more about the complex mechanics of executive compensation.
Watanabe sold 4,375 shares on August 3, 2026, for a total of $114,275. The move was disclosed in a routine SEC filing. But the timing is notable. Just two days later, on August 5, the company reported a stunning turnaround: its first quarterly profit ever.
Why did the CEO sell shares right before good news?
The sale was not a bet against the company. According to the filing, it was a non-discretionary transaction executed solely to cover tax withholding obligations. These obligations kicked in when a batch of Restricted Stock Units (RSUs) vested. In plain English, when the company grants stock to an executive as part of their pay, the government wants its cut. The executive often sells a small portion of those shares to pay the tax bill.
This is standard practice across corporate America. It is not a signal that management is losing faith. In fact, Watanabe still holds more than 950,000 shares, worth about $24.65 million at the close of trading on August 3.
What does Arcutis actually do?
Arcutis Biotherapeutics is a California-based biopharmaceutical company with a sharp focus on skin conditions. Its flagship product is Zoryve (roflumilast cream), which is approved to treat plaque psoriasis and atopic dermatitis. The company has a market cap of $3.3 billion and employs 354 people. It generated $415.62 million in revenue over the trailing twelve months.
Zoryve is the engine driving this growth. The company recently won FDA approval to expand its use to children as young as two years old. It is the seventh FDA approval for the company in four years, a track record that speaks to a disciplined regulatory strategy.
Is Arcutis finally profitable?
Yes, and the numbers are striking. For the second quarter of 2026, Arcutis reported net income of $15 million, or $0.11 per share. That is a sharp reversal from a net loss of $15.9 million ($0.13 per share) in the same quarter last year. Revenue from Zoryve jumped 59% to $129.9 million, driven by strong demand.
The company also maintained positive operating cash flow for the quarter. Management raised its full-year 2026 net product sales guidance to a range of $525 million to $540 million.
What should investors watch next?
The big question is how far Zoryve can go. Arcutis is pursuing additional indications, including for infants (the FDA has already granted a Supplemental New Drug Application) and for vitiligo, which remains in clinical testing. Each new approval opens a larger patient pool and a bigger revenue stream.
That said, the stock is not without risk. Arcutis shares are up nearly 90% year over year, but they are down 6% year to date as of August 6. The market is clearly pricing in high expectations. Any stumble in the pipeline or a slowdown in sales growth could trigger a correction.
What is the bottom line for citizens and investors?
This story is a useful reminder that not every insider stock sale is a red flag. In this case, it was a routine tax maneuver by a CEO who remains heavily invested in his own company. The real story is the company itself: a biotech firm that has crossed from loss to profit, with a flagship product gaining traction and a pipeline that could keep it growing.
For those watching the intersection of business and public health, Arcutis is a case study in how targeted innovation can deliver both medical and financial results. The company is proving that a focused strategy on chronic skin conditions can be both good medicine and good business.
Disclosure: The author holds no position in Arcutis Biotherapeutics.